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Association of Use of an Integrated Specialty Pharmacy With Total Medical
Expenditures Among Members of an Accountable Care Organization
Apurv Soni, BA; Brian S. Smith, PharmD; Thomas Scornavacca, DO; Bill McElnea, MPP; Alice Shakman, MBA; Eric Dickson, MD, MHCM; David D. McManus, MD, ScM
Introduction
Use of integrated specialty pharmacies within Accountable Care Organizations (ACOs) optimizes
medication adherence, increases care coordination with physicians, and reduces medication-related
adverse events.1-3 They may also decrease health care costs for patients because medication
coordination and fulfillment could reduce adverse events and improve underlying conditions, which
in turn decreases health care visits. We examined the association between the use of integrated
specialty pharmacies and total medical expenditure (TME) among the members of the largest ACO in
central Massachusetts.
Methods
Data for this retrospective matched cohort study were extracted from the UMass Memorial Medicare
ACO (UMMACO) from January 2016 through December 2018. Patients of all ages receiving care from
a specialty department were assigned to the intervention group if they were enrolled in the
UMMACO integrated specialty pharmacy at the start of the study period and the control group if they
were not. Their status did not change throughout the study period. To account for baseline
differences between the groups, patients were matched on age, sex, and level of care based on the
UMMACO risk stratification model for care management. Stratification was determined by a
committee within UMMACO that accounts for complexity of patient care, including readmission,
emergency department utilization, postacute care, and chronic disease management. Patients were
matched without replacement. The outcome was the per-member per-month costs (PMPM) of TME,
which were calculated for each month during the study period. We used multilevel generalized linear
models to estimate the association of integrated specialty pharmacy use and PMPM, allowing us to
account for repeated measurements among patients. Postestimation calculations were made for
difference-in-difference analysis and statistical significance was assessed at 95% confidence levels
(eAppendix in the Supplement). Results were considered significant at P < .05 in 2-tailed tests.
Analysis for this study was done in December 2019 and was performed using Stata software,
version 15 (StataCorp). This study followed the Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE) reporting guideline. The study was reviewed by the University of
Massachusetts Medical School institutional review board, and was exempted from informed consent
because it used secondary data analyses of deidentified data.
Results
Patients enrolled in UMMACO who used the organization’s integrated specialty pharmacy were
younger compare with those who did not (median [SD] age, 63 [12.8] years vs 70.6 [12.8] years;
P = .01) (Table 1). Matching increased comparability between the 2 groups. After adjusting for
comorbidities, PMPM were similar in 2016 but increased for patients who did not use the integrated
specialty pharmacy while decreasing for those who did (Table 2). Costs decreased by $267 (95% CI,
−$1586 to $1052) for those who did use integrated specialty pharmacy while increasing by $1007
(95% CI, $270 to $1743) for patients who did not. The difference of difference for average net savings
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of integrated specialty pharmacy users vs nonintegrated specialty pharmacy users was $1274;
however, this difference was not statistically significant (95% CI, −$215 to $2764) for the sample in
this study.
Discussion
Our findings suggest that integrated specialty pharmacy use by patients enrolled in UMMACO is
associated with net savings of more than $1000 per month from 2016 to 2018 compared with
matched counterparts within UMMACO who did not use an integrated specialty pharmacy. Although
not statistically significant, the magnitude of health care savings is notable in the context of previous
findings of savings of as little as $34 (95% CI, $15-$52) for Medicare ACO patients (in a 2016 study
Table 1. Characteristics of Patients Enrolled in the UMass Memorial Medicare Accountable Care Organization Included in This Study,
Based on Their Integrated Specialty Pharmacy Use
Characteristic
Total patients, No.
(%) (N = 9302)














Age, mean (SD), y 71.2 (12.4) 63.6 (12.8) 70.6 (12.1) <.01 63.6 (12.8) 65.3 (14.0) .29
Women 4911 (52.8) 72 (59.8) 1636 (56.9) .50 72 (59.8) 112 (61.3) .79
Level of carea
1, least complex 1767 (19.0) 30 (25.0) 578 (20.1)
.45
30 (25.0) 42 (23.3)
.99
2 2707 (29.1) 27 (22.8) 633 (22.0) 27 (22.8) 40 (21.8)
3 1991 (21.4) 18 (15.2) 552 (19.2) 18 (15.2) 29 (16.0)
4 1488 (16.0) 18 (15.2) 546 (19.0) 18 (15.2) 31 (17.2)
5, most complex 1349 (14.5) 26 (21.7) 566 (19.7) 26 (21.7) 39 (21.7)
Target conditions,
mean (SD), No.
1.9 (1.0) 2.0 (1.0) 2.0 (1.1) .98 2.0 (1.0) 2.1 (1.1) .42
Mental comorbidities,
mean (SD), No.
2.0 (0.5) 2.0 (0.3) 1.9 (0.5) .43 2.0 (0.3) 2.0 (0.4) .99
PMPM, mean (SD), $b
2016 1073 (1561) 1538 (1972) 1206 (1620) .03 1538 (1972) 1466 (1974) .76
2017 1716 (3133) 2017 (3492) 1935 (3143) .78 2017 (3492) 2171 (3736) .72
2018 1534 (3192) 1978 (2754) 2109 (3862) .71 1978 (2754) 2665 (3404) .07
Abbreviation: PMPM, per-member per-month costs.
a Level of care was defined by the care management model of the accountable care
organization and included patients’ demographic information and comorbidities.
b PMPM estimates are rounded to the nearest US dollar.
Table 2. Mean PMPM for Users of Integrated vs Nonintegrated Specialty Pharmacy Among Patients Enrolled
in the UMass Memorial Medicare Accountable Care Organizationa
Year(s)
Integrated specialty pharmacy use, PMPM point
estimate (95% CI), $
Cost difference point
estimate (95% CI), $
Difference of cost estimate
difference (95% CI), $No Yes
Annual
2016 2052 (1113 to 2991) 2121 (304 to 3938) −69 (−1563 to 1425) NA
2017 2673 (1966 to 3379) 2132 (369 to 3895) 541 (−854 to 1936) NA




621 (−88 to 1329) 11 (−1316 to 1338) NA 610 (−883 to 2103)
2018 vs
2017
386 (−181 to 953) −278 (−1550 to 995) NA 664 (−727 to 2056)
2018 vs
2016
1007 (270 to 1743) −267 (−1586 to 1052) NA 1274 (−215 to 2764)
Abbreviations: NA, not applicable; PMPM,
per-member per-month costs.
a Results based on multivariable multilevel generalized
models after users and nonusers of integrated
specialty pharmacy were adjusted for age, sex, and
level of care, specialty of department providing care,
and comorbidities.
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of 15 592 600 participants)4 and savings of $114 (95% CI, $50-$178) among clinically vulnerable
populations participating in a Medicare ACO (in a 2015 study of 8 673 823 participants).5
The results from our study should be interpreted in the context of the limited number of
patients who used the integrated specialty pharmacy in our sample and the focus on patients
receiving specialty care. While patients’ ability to opt into the integrated specialty pharmacy was not
conditioned on a health insurance plan, unobserved patient characteristics and preferences may
inform their choice. We made attempts to reduce bias from confounding by matching on key
variables and adjusting for comorbidities and type of specialty department providing care. However,
additional analyses and future studies (ie, a randomized cluster trial) are needed to identify the
savings attributable directly to integrated specialty pharmacy use. Matching on key covariates
improved comparability but limited our sample size to patients who could be matched on those
variables. Nevertheless, our findings underscore the potential of specialty pharmacies to reduce
TME.6 In the current value-based care landscape, the ability to use data to guide strategic
interventions and provide analysis is essential for any ACO or value-based program. Finding scalable
interventions that provide the full constellation of success for patients, health care professionals,
and ACOs is exceptionally difficult. The integration of specialty pharmacies into care management
models of care delivery has the promise to fulfill this goal.
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